soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Updates in Medicine Semaglutide cardiovascular outcomes align more

Category: Clinical Trials & Real-World EvidenceWritten and Reviewed By: Pharmacally Medical News DeskAt European Society of Cardiology Congress 2025 in Madrid happening between August 29 to 1 September 2025, Novo Nordisk reported that Wegovy (semaglutide 2.4 mg) was linked to a 57% lower risk of heart attack, stroke, or death compared with tirzepatide in people

Try Citrucel caplets today for the effective fiber supplement youve been looking for

HSA eligibility for semaglutide injections depends on medical necessity and whether your plan qualifies the medication as a covered preventive or therapeutic benefit

Here's how to protect yourself from scammers online.

Learn about potential interactions and the best timing for both.

Many patients wonder whether GLP-1 weight loss therapy is safe after cholecystectomy